# 2025-11769: FDA Starts Talks on Another Round of Generic Drug Fees

2025-11769, Generic Drug User Fees; Consultation Meetings on Reauthorization of Generic Drug User Fee Amendments for Fiscal Years 2028-2032; Request for Notification of Intention to Participate, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2025-06-26, effective 2025-09-04; PRIA reads it as touching household money (as of 2026-11-05).

- Canonical: https://policyrisk.com/federal-register/2025-11769
- As of: 2026-11-05
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-11769
- Title: Generic Drug User Fees; Consultation Meetings on Reauthorization of Generic Drug User Fee Amendments for Fiscal Years 2028-2032; Request for Notification of Intention to Participate
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 90 FR 27323
- Published: 2025-06-26
- Effective: 2025-09-04
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-11-05

## In one line

FDA Starts Talks on Another Round of Generic Drug Fees

## Summary

The FDA is gearing up to renew its Generic Drug User Fee program for 2028-2032 and wants groups like patients, doctors, and scientists to join monthly talks starting fall 2025. These fees help speed up generic drug approvals, so staying involved means smoother, faster access to affordable meds. If you want in, let the FDA know by September 4, 2025, and get ready for some important, ongoing conversations!

## Abstract

The Food and Drug Administration (FDA or Agency) is issuing this notice to request that interested parties, including patient and consumer advocacy groups, health care professionals, and scientific and academic experts notify FDA of their intent to participate in periodic consultation meetings on the reauthorization of the Generic Drug User Fee Amendments (GDUFA) for Fiscal Years (FYs) 2028-2032. At the end of September 2027, new legislation will be required for FDA to continue collecting generic drug user fees for subsequent fiscal years for the generic drug program. The Federal Food, Drug, and Cosmetic Act (FD&C Act) requires that FDA consult with a range of interested parties in developing recommendations for the next GDUFA program. The FD&C Act also requires that FDA hold continued discussions with patient and consumer advocacy groups at least monthly during FDA's negotiations with the regulated industry. The purpose of this request for notification is to ensure continuity and progress in these monthly discussions by establishing consistent representation by interested parties.

## Effects PRIA read

- Opportunity to Join Monthly GDUFA Consultations: benefit, low. If you are a patient or consumer advocacy group, a health care professional, or a scientific or academic expert, you may notify the FDA by September 4, 2025 to join monthly consultation meetings about reauthorizing the Generic Drug User Fee program. Meetings are expected to start in the Fall of 202…
- GDUFA Funding May End After September 2027: cost, medium. The notice states that at the end of September 2027 new legislation will be required for FDA to continue collecting generic drug user fees. If new legislation is not enacted by the end of September 2027, FDA will no longer be able to collect user fees for subsequent fiscal years to fund human gener…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2025-11769 on federalregister.gov](https://www.federalregister.gov/documents/2025/06/26/2025-11769/generic-drug-user-fees-consultation-meetings-on-reauthorization-of-generic-drug-user-fee-amendments)
- [2025-11769 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-06-26/pdf/2025-11769.pdf)

## Related
- [Previous: 2025-11768, Intertek Testing Services NA, Inc.: Grant of Expansion of Recognition](https://policyrisk.com/federal-register/2025-11768)
- [Next: 2025-11770, Combined Notice of Filings #1](https://policyrisk.com/federal-register/2025-11770)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-11769 (as of 2026-11-05).
